Pipeline


Sanofi's Complete R&D Portfolio

Sanofi’s research focuses on finding innovative solutions to major public health challenges, including rare diseases, diabetes, immunology. cancer, multiple sclerosis and more.

NeoGAA Clinical Trial

NeoGAA is an investigational enzyme replacement therapy being studied for the treatment of Pompe disease. Learn more about the ongoing Phase 3 clinical trial.



With science and patients at the center of what we do, Sanofi Genzyme continues to focus on developing scientific approaches and novel therapies for complex and debilitating diseases.

Explore our pipeline to see highlights of our research programs in various stages of clinical development.

Items marked with ^ are being developed in collaboration with Regeneron,  and with * are being developed in collaboration with Alnylam®. Items shown with a denote a Phase 2/3 trial.

Technology The platform or technologic approach upon which a treatment is based; either chemically synthesized like a small molecule or polymer drug, or biologic like a protein, antibody, or cell therapy.
Phase I Clinical trials on small number of human subjects, usually healthy, primarily to assess safety and potential side effects at different dosages.
Phase II Clinical trials on affected patients, primarily to test efficacy; usually randomized and placebo-controlled.
Phase III Clinical trials on affected patients to further test efficacy, benefits, and potential side effects; usually randomized, placebo-controlled, and blinded.
Immunology
Dupilumab^
Asthma
mAb
Phase III
Dupilumab^
Nasal Polyposis
mAb
Phase III
Dupilumab^
Eosinophilic esophagitis
mAb
Phase II
SAR100842
Systemic Sclerosis
mAb
Phase II
SAR156597
Systemic Scleroderma
mAb
Phase II
SAR439794
Peanut Allergy
mAb
Phase I
SAR440340
Asthma & COPD
mAb
Phase I
Oncology
Isatuximab
Relapsed Refractory Multiple Myeloma

mAb

Phase III
cemiplimab^
1st Line Non-small Cell Lung Cancer

mAb

Phase III
cemiplimab^
Cutaneous Squamous Cell Carcinoma

mAb

Phase II
Isatuximab
Acute Lymphoblastic Leukemia

mAb

Phase II
cemiplimab^
Advanced BCC
mAb
Phase II
SAR566658
Solid tumors

mAb

Phase II
cemiplimab^
Head & Neck Cancer
mAb
Phase I
SAR439459
Metastatic Melanoma
mAb
Phase I
SAR408701
Solid tumors

mAb

Phase I
SAR428926
Solid tumors

mAb

Phase I
Rare Diseases
Patisiran*
hATTR Amyloidosis
RNAi
Phase III
Fitusiran*
Hemophilia
RNAi
Phase III
NeoGAA
Pompe disease, 2nd generation enzyme
protein-based therapy
Phase III
Olipudase Alfa
Acid Sphingomyelinase Deficiency (ASMD)
protein-based therapy
Phase II
venglustat
Fabry disease
small molecule
Phase II
venglustat
Parkinson's disease with a GBA mutation
small molecule
Phase II
venglustat
Gaucher Type 3
small molecule
Phase II

The agents mentioned here are investigational and have not been approved by the US Food and Drug Administration (FDA) or any other regulatory agency worldwide for the uses under investigation.

In addition to the candidates in clinical development, we are conducting earlier stage research in a range of therapeutic areas including genetic diseases such as cystic fibrosis, spinal muscular atrophy, and Lebers congenital amaurosis type 1. We have several programs in multiple sclerosis with molecules addressing areas of unmet need, using approaches such as immunomodulation, neuroprotection, and remylination.

Last Updated: 12/12/2017
GZUS.GZ.16.10.2192(8)
infoBox